NLS Pharmaceutics (NLSP) has released an update.
NLS Pharmaceutics Ltd. has announced the upcoming termination of its CFO, Elena Thyen, effective October 31, 2024, in anticipation of a prospective merger with Kadimastem Ltd. The departure is part of a planned reorganization and does not stem from any internal disputes or issues with company policies. The company is also preparing to enter a definitive merger agreement, although there is no guarantee that the merger will proceed as expected.
For further insights into NLSP stock, check out TipRanks’ Stock Analysis page.